Digital Diabetes Management Market Report 2025

This Digital Diabetes Management market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The digital diabetes management market size has grown exponentially in recent years. It will grow from $15.9 billion in 2024 to $19.27 billion in 2025 at a compound annual growth rate (CAGR) of 21.2%. The growth in the historic period can be attributed to rising diabetes prevalence, technological advancements, personalized healthcare, regulatory support, telehealth and remote monitoring.

The digital diabetes management market size is expected to see exponential growth in the next few years. It will grow to $47.21 billion in 2029 at a compound annual growth rate (CAGR) of 25.1%. The growth in the forecast period can be attributed to continued diabetes epidemic, artificial intelligence (ai) and machine learning, data integration, remote care models. Major trends in the forecast period include continuous glucose monitoring (cgm), insulin delivery systems, mobile apps and wearables, patient engagement and education.

The growing prevalence of diabetes is expected to drive the demand for digital diabetes management devices and associated services, thereby increasing the market's demand. Diabetes is a leading cause of death, with 30% of the reduction in life expectancy attributed to diabetes diagnosis. For example, in June 2024, the NHS England, a UK-based government agency, reported a nearly 25% increase in the number of individuals under the age of 40 at risk of type 2 diabetes, rising from 173,166 in 2022 to 216,440 in 2023. This growing prevalence of diabetes is fueling the demand for digital diabetes management solutions.

The rise in healthcare expenditures is predicted to fuel the growth of the digital diabetes management market. Healthcare expenditures encompass the total amount spent on healthcare-related services, products, and activities within a specified period, whether at an individual, community, national, or global level. The increased healthcare spending, combined with improved access to healthcare services and a growing number of diabetes diagnoses, leads to greater investments in research and development. This, in turn, results in the advancement of digital and advanced diabetes care devices, such as enhanced glucose monitoring systems, insulin delivery devices, and digital health solutions. For example, in 2022, the Office for National Statistics reported that UK healthcare spending reached approximately $354.88 billion (£283 billion), reflecting a nominal increase of 0.7% compared to the previous year. As a result, the rising healthcare expenditure is expected to drive the growth of the digital diabetes management market in the coming years.

Several companies are placing increasing emphasis on designing AI-powered connected apps to enhance the user experience, a trend gaining significant popularity in the digital diabetes management market. Prominent companies in this market, such as OneDrop, Ascencia, and Dario, are shifting their focus towards making their products appear more like stylish gadgets rather than traditional medical devices. As an example, Medtronic plc and IBM Watson Health recently introduced the AI-powered Sugar.IQ smart diabetes management app, designed to simplify and enhance daily diabetes management.

Key players in the digital diabetes management market are also introducing innovative products to gain a competitive edge. The Dexcom ONE Continuous Glucose Monitoring System is a user-friendly, real-time continuous glucose monitoring solution that eliminates the need for painful fingerpricks. For instance, in April 2022, DexCom, Inc., a US-based company specializing in continuous glucose monitoring systems, launched the Dexcom ONE Continuous Glucose Monitoring System. This real-time CGM aims to be more cost-effective and accessible for individuals with diabetes in the UK and is currently undergoing review for inclusion in UK regional drug tariffs. The Dexcom ONE system, comprising a wearable sensor and transmitter, offers continuous glucose monitoring and sends real-time data to a compatible smart device through the user-friendly Dexcom ONE mobile app. This technology eliminates the need for painful fingerpricks and provides trend arrows for informed treatment decisions, along with customizable alerts to prevent dangerous glucose fluctuations.

In May 2023, Medtronic PLC, an Ireland-based medical technology company, acquired EOFLOW Co., Ltd. for $738 million. This acquisition enables Medtronic to establish an advanced closed-loop system for more automated diabetes management by combining tubeless devices with their continuous glucose monitors and meal-detection algorithm. EOFLOW Co., Ltd. is a South Korea-based provider of digital and smart wearable diabetes management solutions.

Digital diabetes management involves the utilization of electronic healthcare solutions to remotely monitor, analyze, and oversee the well-being of individuals with diabetes or those at risk of developing the condition. Through the use of digital diabetes management, people can enhance their health outcomes by effectively self-managing their diabetes.

The primary categories of products and services within the field of digital diabetes management encompass devices, applications, data management software, and platforms, as well as various services. A data management platform (DMP) serves as a software tool for collecting and managing data, enabling companies to create distinct audience segments that can be leveraged to target specific individuals and settings in online advertising campaigns. Various device types, including handheld and wearable devices, find application across different sectors such as self or home healthcare, hospitals, specialty diabetes clinics, and other healthcare settings.

The digital diabetes management market research report is one of a series of new reports that provides digital diabetes management market statistics, including digital diabetes management industry global market size, regional shares, competitors with a digital diabetes management market share, detailed digital diabetes management market segments, market trends and opportunities, and any further data you may need to thrive in the digital diabetes management industry. This digital diabetes management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Major companies operating in the digital diabetes management market include Bayer AG, Medtronic PLC, Roche Diagnostics Ltd., Dexcom Inc., Abbott Laboratories, Ascensia Diabetes Care Holdings AG, Insulet Corporation, B. Braun Melsungen AG, Tandem Diabetes Care Inc., LifeScan Inc., AgaMatrix Inc., Glooko Inc., DarioHealth Corp, One Drop, Dottli Oy, Ypsomed Holding AG, ARKRAY Inc., ACON Laboratories Inc., Becton, Dickinson and Company, Care Innovations LLC, Health2Sync Inc., Emperra GmbH E-Health Technologies, Azumio Inc., Decide Clinical Software GmbH, pendiq GmbH Moers, Health Arx Technologies Pvt Ltd., Sanofi SA, Johnson & Johnson Co, Novo Nordisk AS, Terumo Corporation, TidePool, AgaMatrix Medical Devices Ltd.

North America was the largest region in the digital diabetes management market in 2024. Western Europe was the second largest region in the digital diabetes management market report. The regions covered in the digital diabetes management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the digital diabetes management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The digital diabetes management market consists of revenue generated by the companies offering devices and services that manage blood glucose levels in the human body. These devices play a vital role in the care of diabetes patients with the management of patients' blood glucose levels and controlling their conditions. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.